Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
about
Gamma-herpesvirus latency requires T cell evasion during episome maintenanceAdoptive T-Cell ImmunotherapyUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsThe interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and diseaseTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaT cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.The synthesis of truncated polypeptides for immune surveillance and viral evasion.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in ChinaThe interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersG-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation.mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.HLA associations in classical Hodgkin lymphoma: EBV status matters.Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis.Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target.Finding a place for tumor-specific T cells in targeted cancer therapyComplete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferDendritic cells, DRiPs, and DALIS in the control of antigen processing.Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes.Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseTargeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.Identifying novel genes and chemicals related to nasopharyngeal cancer in a heterogeneous network.Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis.Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinomaCritical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificitiesAdenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer.Prospects of a novel vaccination strategy for human gamma-herpesviruses.Immunotherapy for EBV-associated malignancies.Hodgkin disease and the role of the immune system.Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.The impact of macroautophagy on CD8(+) T-cell-mediated antiviral immunity.
P2860
Q24803420-712F6246-E45A-4767-9BCF-415FC71D6C28Q26782845-BA5424C8-13B2-4412-B34B-8AE6B1E3F64CQ26823898-0A566D32-0112-438A-ACE6-1DA0B2134B1FQ26998401-4E51C72F-553E-4B5F-B090-8ABC6FA506A2Q27016002-54DFE73B-225D-40AA-B7C1-03F276C64024Q33519520-9A362676-AD2D-453A-8833-A83EFD23F19DQ33526302-5E64696D-7C36-4E62-95F0-3335E88EED24Q33588711-28C6EFC1-0136-4ACC-9BD8-BBB22CFBF120Q34092709-8C8240CF-8ADC-438D-8F60-94DD5083DF38Q34166497-BE11E867-8597-43A0-AA9A-58777A0F41B2Q34166602-86E5DDC6-4CFA-4E85-B43A-5F685BDC2249Q34303299-4EA71EE1-64B1-49A4-B116-B37E82606672Q34317937-A5CE23F8-66B5-4D1A-A3FB-DF2E1C5D7E8BQ34341716-B709896D-3233-436F-B8C6-7F3E5EF67294Q34539792-B32778A9-9804-4EB0-B0B0-1AA1093D7476Q34658852-964CB805-A4A6-4146-A42E-B456913E5766Q35121627-E86EB029-4D97-4232-A803-CB764524A719Q35554572-7DD9A54D-CB34-4BD5-A9CD-90F3FF06EF16Q35616090-EE9F827B-65BD-4EA1-BB1E-E5F47F9A044DQ35775750-E84E09D3-38F9-4713-94C4-04BEF919D1BCQ35990075-A3F5A5EA-2D54-4979-9FFB-80FCC869F184Q36059593-B7EA0D99-2561-48A0-BA26-253ADF1F536AQ36266479-430130A4-4F93-4D2D-BA40-1E14B4BBF231Q36267161-FD18BEF4-2891-4535-90A7-CD7E3D027112Q36399179-3C2883FE-2790-4841-A105-D7A862A640E8Q36399195-7DC1F2AE-0251-48C4-A71A-266F1217C65CQ36399791-A23D6E3F-DB73-4289-B7C2-4D74CCBBD4C7Q36835091-4BF91E94-E7DA-41ED-9124-4C8933A467FFQ36872700-150CF0BF-260D-4B31-937B-3039F0E3F0BEQ36943860-5BC7E898-2034-4066-93D1-919358B08BC0Q37117769-578E2E5D-9BE1-4FB2-B05A-CC1B7D555CCDQ37286445-8732D5FD-4FF0-4932-8477-E2CF0CB84023Q37319382-6EB928F8-8802-40F1-A141-24AD5453C405Q37713951-F29D265D-4B87-4D20-8F9E-B4997197FFB7Q37773234-D00F26B7-E83D-440E-BB6F-F03127B6D7B5Q37780705-414921D2-C715-436D-AD32-B514FC1D5116Q37845178-7BBEF38C-D293-495E-B5E6-50C323DAC2BAQ37850445-F3D2E06D-96BA-41E2-B3B3-5AF079919983Q37854496-27BAA0FA-8B04-4449-8FC1-34400CC48F7FQ38129080-B2411332-38D0-451A-90C1-C69F44A4D5D6
P2860
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@ast
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@en
type
label
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@ast
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@en
prefLabel
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@ast
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@en
P2093
P2860
P356
P1476
Evidence for the presentation ...... eptides to CD8+ T lymphocytes.
@en
P2093
Cliona M Rooney
Helen E Heslop
Helen Y Wang
Judy Tellam
Kui Shin Voo
Malcolm K Brenner
Rong-Fu Wang
P2860
P304
P356
10.1084/JEM.20031219
P407
P577
2004-02-09T00:00:00Z